KetoSwiss secures $4 million

Despite migraine being the 3rd most common disease in the world, there is still an evident lack of prevention and treatment options, which leaves many patients unable to participate in everyday life fully. Recently, the role of metabolism in migraine has gained attention, paralleled by increasing awareness of its role in various psychiatric and neurodegenerative conditions.

KetoSwiss develops products which improve brain energetics, a common denominator of many neurological and psychiatric diseases for which no treatment method is currently available. MigraKet, the company’s first flagship medical food for migraine and a product of the Brain Ritual brand, pairs the brain’s most ancient fuel – ketone bodies – with crucial micronutrients necessary for the brain’s energy metabolism. With this, KetoSwiss offers a holistic, clinically tested, and patent-protected solution.

Thanks to the latest financing round, the KetoSwiss is well-positioned to achieve its ambitions, including launching its go-to-market brand Brain Ritual in the U.S. market in H1 2023. Its direct launch preparations include hiring key team members and simultaneously expanding the U.S.-based arm of the company. Moreover, KetoSwiss will use the investment to achieve R&D and clinical development milestones. It will conduct exploratory studies with a U.S. partner institution to examine the effects of MigraKet on brain function and its possible implications for patients with depression or other mental health conditions. Further research will be conducted on potential new compounds and molecules.

The William K. Warren Foundation, which supports research into neuropsychiatric disorders, led the financing round. Other participating investors include two U.S.-based Venture Capital firms: R42, which finances deep science ventures with a special focus on longevity, AI and biotechnology, and Healthspan Capital, a venture fund investing in longevity biotech (“LongBio”) and regenerative medicine.

The Baszucki Group, which focuses on research into the role of the intersection between metabolism, psychiatry, and neuroscience in transforming mental health outcomes, joined the round. Alongside other funds and business angels, Ortho Innovations, a spinoff from the Orthomol family business, also contributed to the pre-seed round, bringing its nutraceutical and medical food expertise to the startup.

“We are very happy to close this round with a substantial capital increase that will be crucial for launch-related activities and R&D and further team expansion. This is a very exciting time for KetoSwiss”, says Dr Elena Gross, the CEO and founder of KetoSwiss who was a chronic migraine sufferer.

(Press release/RAN)